Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers.

Disease markers - 1 Jan 2006

O'Connor Kevin C, Roy Sushmita Mimi, Becker Christopher H, Hafler David A, Kantor Aaron B

Abstract excerpt

Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Biomarkers
Share to Inflammation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Sclerosis

Share to Neurodegenerative Diseases

Share to Phenotype

Share to Proteomics

Source

Open in PubMed Open full text

Identifiers

PMID: 17124343
DOI: 10.1155/2006/670439
PMCID: PMC3851054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17124343-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers.PMID 17124343Read ↗

Development of biomarkers in multiple sclerosis.Semantic proximity Read ↗

Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis?Semantic proximity Read ↗

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosisSemantic proximity Read ↗

Biomarkers in Multiple Sclerosis: An Up-to-Date OverviewSemantic proximity Read ↗

The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical UseSemantic proximity Read ↗

Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain–Barré syndromeSemantic proximity Read ↗

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicineSemantic proximity Read ↗

Multiple sclerosis: individualized disease susceptibility and therapy response.Semantic proximity Read ↗

Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitusSemantic proximity Read ↗

New antigenic candidates in multiple sclerosis: Identification by serological proteome analysisSemantic proximity Read ↗

Molecular markers in the CSF proteome differentiate neuroinflammatory diseasesSemantic proximity Read ↗

Multiple sclerosis: genetics, biomarkers, treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.